Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (FLR) for allegedly concealing significant cost overruns and execution problems on key infrastructure projects, leading to a sharp decline in stock value and investor confidence [1][3][4]. Company Overview - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally, with its Urban Solutions segment being the largest revenue driver among its three segments [2]. Allegations and Issues - The lawsuit claims that FLR concealed cost overruns and execution issues on major projects such as the Gordie Howe International Bridge, I-635/LBJ, and I-35, which were impacted by subcontractor errors, supply chain inflation, and construction delays [3]. - The company allegedly overstated its risk mitigation strategies and failed to disclose the full impact of reduced client spending and macroeconomic uncertainty [3]. Financial Performance - Despite the ongoing issues, FLR reaffirmed its financial guidance in May 2025. However, on August 1, 2025, the company reported second-quarter results that significantly missed expectations, with non-GAAP EPS of $0.43 (missing by $0.13) and revenue of $3.98 billion (missing by $570 million) [4]. - Following these disappointing results, FLR cut its full-year guidance and experienced a stock price drop of 27.04%, closing at $41.42 on August 1, 2025. Analysts subsequently downgraded the stock due to lost confidence in management's disclosures and project oversight [4].

Group 1 - A class action has been filed against LifeMD, Inc. (NASDAQ: LFMD) on behalf of investors who acquired its securities between May 7, 2025, and August 5, 2025 [1][2] - The allegations include that LifeMD misled investors about its competitive position and failed to properly account for rising customer acquisition costs, particularly in its RexMD segment and for obesity treatment drugs [2] - Following the announcement of its second quarter 2025 results and a revision of its full-year guidance, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3] Group 2 - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can choose to remain absent class members if they do not wish to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5]

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose a material investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [2][3]. Group 1: Allegations and Investigations - Semler Scientific is accused of not disclosing an investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - The company received an initial civil investigative demand (CID) from the DOJ in July 2017, which investigated whether it violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - On February 11, 2025, Semler Scientific engaged in unsuccessful settlement discussions with the DOJ, raising concerns about a potential lawsuit [3]. Group 2: Financial Impact - Following the revelation of the investigation on February 28, 2025, Semler Scientific's stock price dropped by $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. - After the company announced a settlement agreement with the DOJ for $29.75 million on April 15, 2025, the stock fell by $3.40, or 9.88%, to close at $31.00 on April 16, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must submit their paperwork by October 28, 2025, to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery, and they can remain absent class members if they choose [5].

Core Viewpoint - A class action securities lawsuit has been filed against PubMatic, Inc. due to alleged securities fraud affecting investors between February 27, 2025, and August 11, 2025 [1][2] Group 1: Lawsuit Details - The complaint alleges that PubMatic's management made false statements and concealed critical information regarding a major demand side platform buyer shifting clients to a new platform, leading to reduced ad spend and revenue for PubMatic [2] - The lawsuit claims that the positive statements made by the defendants about PubMatic's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action securities lawsuit has been filed against Fluor Corporation, alleging securities fraud that negatively impacted investors between February 18, 2025, and July 31, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fluor Corporation made false statements regarding the rising costs of infrastructure projects due to subcontractor design errors, price increases, and scheduling delays [2]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, significantly harmed the Company's business and financial results [2]. - The financial guidance provided by Fluor for FY 2025 is described as unreliable and overstated regarding the effectiveness of its risk mitigation strategies [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 14, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Shares of social network Snap Inc. (NYSE: SNAP) fell 6.6% after investment firm Mizuho reportedly initiated coverage on the company with a Neutral rating and a $9 price target. Mizuho purportedly described the company as a “show-me story” and cited weak feedback from Snap’s advertising channels. This analyst action comes on the heels of a federal securities class action lawsuit filed against Snap and certain senior executives, alleging the company presented a ...

Core Viewpoint - Investors in Savara Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged undisclosed information regarding the company's regulatory submissions and business prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that between March 7, 2024, and May 23, 2025, Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on its chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - The lawsuit asserts that the positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Participation Information - Investors who suffered losses on their Savara investments are encouraged to participate in the lawsuit before the lead plaintiff deadline of November 7, 2025 [2]. - Interested parties can contact Glancy Prongay & Murray LLP for more information or to learn about their rights regarding the lawsuit [3][4].

Core Viewpoint - Tandem Diabetes Care, Inc. is under investigation for potential violations of federal securities laws following a malfunction in its insulin pumps that could endanger patients and lead to significant financial losses for investors [1][2]. Company Summary - On August 7, 2025, Tandem disclosed a malfunction in some of its insulin pumps that could lead to a discontinuation of insulin delivery, potentially resulting in hyperglycemia and requiring hospitalization [2]. - The company notified affected customers between July 22 and 24, 2025, about the issue [2]. - Following this announcement, Tandem's stock price dropped by $2.87, or 19.9%, closing at $11.52 per share on the same day, indicating a significant impact on investor value [3]. Legal and Investigation Context - Glancy Prongay & Murray LLP is leading the investigation on behalf of Tandem investors to explore possible claims for recovering losses incurred due to the stock price decline [1][4]. - The law firm has a strong track record in securities litigation, having recovered billions for investors and consistently ranked among the top firms in securities class action settlements [6][7].

Core Viewpoint - Marex Group plc is under investigation for potential violations of federal securities laws following allegations of accounting misconduct, including concealing significant losses and inflating profits through off-balance-sheet entities and misleading disclosures [1][2]. Group 1: Allegations and Financial Impact - A report by NINGI Research claims that Marex has concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, which it controls and trades with, leading to inflated operating cash flow [2]. - Following the allegations, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025, resulting in financial harm to investors [3]. Group 2: Legal and Whistleblower Information - Glancy Prongay & Murray LLP is representing investors in pursuing claims to recover losses related to Marex [2]. - Individuals with non-public information about Marex are encouraged to consider participating in the SEC Whistleblower Program, which offers rewards of up to 30% of any successful recovery made by the SEC [5]. Group 3: About the Law Firm - Glancy Prongay & Murray LLP is a prominent law firm specializing in securities litigation and has a strong track record in recovering billions for investors [6][7].

Core Viewpoint - Tandem Diabetes Care, Inc. is under investigation for potential violations of federal securities laws following a malfunction in its insulin pumps that could endanger patients and impact investors [1][2]. Group 1: Company Issues - On August 7, 2025, Tandem disclosed a malfunction in some insulin pumps that could lead to a cessation of insulin delivery, potentially causing hyperglycemia and requiring medical intervention [2]. - The company notified affected customers between July 22 and 24, 2025, regarding the malfunction [2]. Group 2: Market Impact - Following the announcement of the malfunction, Tandem's stock price dropped by $2.87, or 19.9%, closing at $11.52 per share on August 7, 2025, resulting in financial harm to investors [3].